DV
Dividend Vision

GRTX — Galera Therapeutics Inc

Galera Therapeutics Inc (GRTX)

Its deepest 1-year drawdown was 38.5%.

Galera Therapeutics is a biopharmaceutical company developing small molecule dismutase mimetics to improve cancer treatment outcomes. Its lead programs include tilarginine, in Phase 1/2 trials for treatment-resistant breast cancer, and avasopasem manganese for radiation-induced oral mucositis in head and neck cancer patients. As an early-stage biotech company, it does not currently distribute dividends and is oriented toward capital appreciation rather than income generation.

GRTX key facts

Asset type
Stock
Asset class
Equity
Inception date
11/07/2019
Distribution frequency
None
Last close
$16.28
Market cap
$3,382,312,192
Average volume
1065.0
Beta
2.605
Payout ratio
0.0
P/E ratio
0.1352
Forward P/E
0.0
EPS
$120.44